Chimeric antigen receptor (CAR)
Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses
... mesothelin-redirected chimeric antigen receptor T cells (meso-CAR T cells) and oncolytic adenovirus expressing TNF-α and IL-2, Ad5/3-E2F-D24-TNFa-IRES-IL2 (Ad5/3-OAd-TNFa-IL2) treatment in an ...
18
Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy
... Chimeric antigen receptor-modified (CAR) T cells targeting CD19 (CART19) have shown therapeutical activities in CD19+ ...(BBB)-penetrating CAR T cells as a culprit was ...
5
Critical factors in chimeric antigen receptor-modified T-cell (CAR-T) therapy for solid tumors
... of chimeric antigen receptor-modified T-cell (CAR-T) therapy for B-cell lymphocyte malignancies targeting CD19 places it in a rapidly growing field in cancer immunotherapy for both ...
12
Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia
... priority. Chimeric antigen receptor-modified T cell (CAR-T) therapy, as one of the most promising targeted immunotherapies, has drawn extensive attention and resulted in multiple ...
7
Protein L: a novel reagent for the detection of Chimeric Antigen Receptor (CAR) expression by flow cytometry
... a chimeric antigen receptor (CAR) combines the beneficial effects of both antibody and T-cell mediated immune ...surface antigen fused to extracellular spacer and transmembrane domains ...
6
Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance
... CD19 CAR T cells against ALL, the first data showing efficacy in relapsed/refractory ALL patients were pub- lished, with CRs observed responses in two children and five adults in separate studies, including ...
12
MAGE-A1 in lung adenocarcinoma as a promising target of chimeric antigen receptor T cells
... Previously, we produced a human anti-MAGE-A1 scFv and synthesized an immunotoxin [33]. To confirm the legitimacy and suitability of MAGE-A1 as a target anti- gen for LUAD treatment, we tried to construct a mCAR by ...
18
Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies
... vedotin; CAR: Chimeric antigen receptor; cCAR: Compound CAR; CIK: Cytokine-induced killer; CLL: Chronic lymphocytic leukemia; CML: Chronic myeloid leukemia; CR: Complete remission; CTL: ...
20
Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia
... when chimeric antigen receptor (CAR)-engineered T cells were ap- proved by FDA for children and young adults with R/R ALL [39 – ...of antigen target has been reported to be a common ...
11
CRISPR-Cas, a robust gene-editing technology in the era of modern cancer immunotherapy
... Cancer immunotherapy has been emerged as a promising strategy for treatment of a broad spectrum of malig- nancies ranging from hematological to solid tumors. One of the principal approaches of cancer immunotherapy is ...
17
Open innovation and external sources of innovation An opportunity to fuel the R&D pipeline and enhance decision making?
... • Novartis has also successfully collaborated with selected institutions such as the Dana–Farber Can- cer Institute on cancer alliances or the University of Pennsylvania on the chimeric antigen ...
14
The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL
... as chimeric antigen receptor (CAR) T cells, which have revolutionized the treat- ment of pediatric patients with relapsed or refractory B-cell acute lymphoblastic ...of CAR T-cells are ...
12
Clinical trials of CAR-T cells in China
... therapy. Chimeric antigen receptor (CAR)-engineered T cells are widely studied for cancer ...CD19-specific CAR-T cells, tisagenlecleucel, have been recently approved for clinical ...
10
Hong_unc_0153D_17522.pdf
... to antigen stimulation, and c) survive long- term in vivo ...of chimeric antigen receptor T cells (CAR-Ts) against solid tumors, with an emphasis on CD30-specific CAR-Ts, will be ...
143
Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy
... APCs: Antigen-presenting cells; B7-H1: B7-homolog 1; BTLA: B and T lymphocyte attenuator; CAR: Chimeric antigen receptor; CD137: 4-1BB; CLL: Chronic lymphocytic leukemia; CTL: Cytotoxic ...
9
Case Report Achievement of disease control with dasatinib after CAR T-cell therapy for relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia: a case report and literature review
... and chimeric antigen receptor-engineered T (CAR T)-cell therapy mark crucial advancements in the treatment of ...received CAR T-cell therapy and responded well until a third relapse ...
7
From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma
... uses chimeric antigen receptor-modified T cells (CAR-T) or genetically modified NK cells, has been shown to be a promising strategy for the treatment of ...HCC. CAR-T can specifically ...
21
Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade
... IX; CAR : chimeric antigen receptor; CCK: cholecystokinin; CSF1: colony-stimulating factor 1; CSF1R: colony-stimulating factor 1 receptor; CR: complete response; CTLA-4: cytotoxic ...
16
Recent advances in nanotheranostics for triple negative breast cancer treatment
... cancer; CAR: Chimeric antigen receptor; CIK: Cytokine-induced killer; CTLs: Cytotoxic T lymphocytes; EPR: Enhanced permeation and retention; ER: Estrogen receptor; FDA: Food and Drug ...
22
Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential?
... revolutionized the treatment landscape for many advanced cancers. Notably, the use of immune checkpoint inhibitors has demonstrated durable responses in various malignancies. However, the response to such treatments is ...
14